Alnylam Pharmaceuticals Gross Profit Margin
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Gross Profit Margin
Gross profit margin is the difference between sales and the cost of goods sold divided by revenue. It expresses the relationship between gross profit (sales - cost of goods sold) and sales revenue. More specifically, gross profit margin represents the percentage of each dollar of a company's revenue that is available to cover fixed costs after paying for the goods or services that were sold.
If a company produces widgets and earns $32 million in sales but pays $24 million for the items sold, then the company's gross profit margin would be ($32m - $24m)/$32m = %25.
Learn More
You may also be interested in these ALNY related companies
ALNY News
Listen to $ALNY Q4 2011 earnings call (EPS -0.33 vs est -0.32) - live at 04:30 PM, ondemand after - http://stks.co/2Krr
about 3 days ago by earningscast
about 3 days ago by earningscast
$ALNY Reports Q4 EPS $(0.33) vs $(0.32) Est; Revenues $20.50M vs $20.90M Est
about 3 days ago by Benzinga
about 3 days ago by Benzinga
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 09, 4:00PM Business Wire
Feb 09, 4:00PM Business Wire
Alnylam Scientists Discover Novel Method for Monitoring RNAi Activity in Blood Samples
Feb 09, 8:00AM Business Wire
Feb 09, 8:00AM Business Wire
$ALNY New 52 Week High - Crossed daily highs resistance. Next resistance 13.64 from 11/5/2010.
about 7 days ago by TradeIdeasQuant
about 7 days ago by TradeIdeasQuant
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial Results
Feb 02, 4:00PM Business Wire
Feb 02, 4:00PM Business Wire
Alnylam Pharma (ALNY) Receives Notice of Allowance Covering 2G LNP Platform
Jan 30, 8:03AM Street Insider
Jan 30, 8:03AM Street Insider
Rodman & Renshaw Reiterates Outperform, $12 Target on Alnylam Pharmaceuticals
Jan 20, 6:24AM Benzinga
Jan 20, 6:24AM Benzinga
Alnylam (ALNY) Announces Restructuring: Will Cut 33% of Workforce, Sees $4M in Charges
Jan 19, 6:01PM Street Insider
Jan 19, 6:01PM Street Insider
Alnylam (ALNY) Files Patent Infringement Suit Against Tekmira Pharma Over siRNA Molecules
Jan 17, 9:09AM Street Insider
Jan 17, 9:09AM Street Insider
biotech stocks on fire @upsidetrader fanning flames with $ALNY http://stks.co/1vDB $CELG, $AMGN, $GILD, $SPX
about 31 days ago by SFOmag
about 31 days ago by SFOmag
$RXII $GALE $MRNA $ALNY $CYTR $ARWR RIP140 regulation of diabetes Patent8093223 Czech(RXi Pharmaceuticals) http://stks.co/1tyQ
about 32 days ago by biotech
about 32 days ago by biotech
$ALNY rodman comments: these
results represent a key milestone in the advancement of RNAi as a new
class of therapeutis $MRNA $GALE
about 84 days ago by biotech
about 84 days ago by biotech
$MRNA The long wait is finally over: Systemic RNAi delivery has been proven in Man http://stks.co/1DI9 $GALE $RXII $ALNY
about 84 days ago by biotech
about 84 days ago by biotech
$ALNY $MRNA $GALE http://stks.co/15Ih gene mutation that drops heart-attack risk by as much as 88 %
about 94 days ago by biotech
about 94 days ago by biotech
$MRNA Demonstrates That Its Novel UsiRNA Oligonucleotide Abrogates Cytotoxicity Resulting From microRNA-Like Off-Target Activity $ALNY $GSK
about 103 days ago by biotech
about 103 days ago by biotech
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALNY | 12.15 | -0.90 | -6.90% | 519.17M |
| CTIC | 1.08 | -0.02 | -1.82% | 208.31M |
| GOOG | 605.91 | -5.55 | -0.91% | 196.25B |
| LLNW | 3.98 | -0.12 | -2.81% | 453.32M |
| FITB | 13.35 | -0.17 | -1.29% | 12.27B |
| ASEI | 77.02 | 8.74 | 12.80% | 687.02M |
| MSFT | 30.50 | -0.28 | -0.89% | 256.53B |
| BRCD | 5.80 | -0.14 | -2.36% | 2.85B |
| CSCO | 19.89 | -0.10 | -0.53% | 106.74B |
| ETFC | 9.21 | 0.02 | 0.22% | 2.63B |
